Neurological disorders Archives

News and Trends 14 Dec 2022

PrecisionLife to work on R&D with Ono Pharmaceutical

PrecisionLife Limited has entered into a multi-target discovery and validation partnership with Ono Pharmaceutical Co., Ltd. The R&D collaboration will leverage PrecisionLife’s combinatorial analytics-generated insights to identify novel therapeutic targets and patient stratification biomarkers in central nervous system (CNS) disorders for development by Ono. PrecisionLife analyzes multi-modal datasets including genomic, clinical, and epidemiological data to […]

December 14, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 30 Nov 2022

bit.bio expands portfolio for drug discovery in neurodegenerative and neurological diseases

Cell coding company bit.bio has made three additions to its product portfolio: ioGlutamatergic Neurons MAPT N279K and ioGlutamatergic Neurons MAPT P301S disease models, and early access to its ioGABAergic Neurons. This expands bit.bio’s central nervous system (CNS) portfolio to four disease models and three cell types. bit.bio’s cell products are reprogrammed from human induced pluripotent […]

November 30, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 18 Nov 2022

Beyond Biotech podcast 23: World Antimicrobial Awareness Week, PsychoGenics

This week, we have three interviews on the theme of antimicrobial resistance (AMR), to mark World Antimicrobial Awareness Week. We spoke with Holger Zimmermann, CEO of anti-infectives company AiCuris; Neil Clark, CEO of Destiny Pharma, and Fredrik Almqvist, co-founder of QureTech Bio. We also have an interview with the chief scientific officer at PsychoGenics, Mark Varney. […]

November 18, 2022

More News! 14 Nov 2022

Minoryx and Neuraxpharm form alliance to get rights to new therapy for rare CNS disease

Minoryx Therapeutics and Neuraxpharm Group have announced a strategic alliance for the European rights to a new therapy for rare central nervous system (CNS) disease. The companies have entered into a license agreement for leriglitazone, currently under European Medicines Agency (EMA) review for the orphan indication X-linked Adrenoleukodystrophy (X-ALD). Under the agreement, Minoryx grants Neuraxpharm […]

November 14, 2022 - 3 minutesmins - By Liza Laws

News and Trends 10 Nov 2022

Minoryx and Neuraxpharm announce license agreement to further X-ALD treatment

Minoryx Therapeutics and Neuraxpharm Group have announced the completion of a strategic license agreement. Minoryx is a biotech company that focuses on the development of treatments for orphan central nervous system (CNS) disorders while the Neuraxpharm Group is a pharmaceutical company focused on CNS therapies. Under the agreement, Minoryx grants Neuraxpharm exclusive European rights to […]

November 10, 2022 - 3 minutesmins - By Liza Laws

More News! 9 Nov 2022

PrecisionLife supports Sosei Heptares to treat chronic diseases in more personalized way

PrecisionLife, developers of precision medicine for chronic diseases, will be supporting biopharmaceutical group, Sosei Heptares, to develop better, more personalized treatment options. Specifically, global techbio PrecisionLife, will assess the precision medicine potential of a neuroscience target nominated by Sosei Heptares, that specializes in structure-based drug design targeting G protein-coupled receptors (GPCRs). Sosei Heptares will leverage […]

November 9, 2022 - 3 minutesmins - By Liza Laws

News and Trends 2 Nov 2022

Alkermes to separate oncology business

Alkermes plc is to explore separating its commercial-stage neuroscience business and development-stage oncology business. The company, its board and external financial and legal advisors plan to explore a separation of the oncology business into an independent, publicly-traded company (Oncology Co.) as part of an ongoing review of strategic alternatives for the oncology business. Alkermes said […]

November 2, 2022 - 4 minutesmins - By Jim Cornall

More News! 26 Oct 2022

Neuraxpharm to commercialize device giving early warning of epileptic seizures

A wearable medical device that can give an early warning of an epileptic seizure has been developed by medical device startup, mjn-neuro. Central nervous system (CNS) specialist Neuraxpharm Group entered the digital health market by signing a commercialization agreement with the developer for mjn-SERAS with exclusivity in Europe. With this agreement, Neuraxpharm increases its end-to-end […]

October 26, 2022 - 4 minutesmins - By Liza Laws

News and Trends 12 Oct 2022

Ascidian Therapeutics launches with $50M to rewrite RNA

Ascidian Therapeutics, a biotechnology company focused on treating human diseases by rewriting RNA, has been launched. With an initial focus on replacing mutated exons at the RNA level, Ascidian’s technology enables therapeutic targeting of large genes and genes with high mutational variance while maintaining native gene expression patterns and levels. This approach is designed to […]

October 12, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 4 Oct 2022

Spinoff Biohaven launches with $258M and “incredible pipeline”

Biohaven Ltd. launched today as a new publicly traded company focused on delivering innovative life-changing treatments for neurological and neuropsychiatric diseases, including rare disorders. As of today, Biohaven has officially begun operating as a separate independent entity as part of the acquisition agreement with Pfizer in May 2022. The company, led by Vlad Coric as […]

October 4, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 29 Sep 2022

NeuShen Therapeutics closes $20M pre-A financing

Chinese biotech company NeuShen Therapeutics, Inc. has closed an approximately $20 million series pre-A financing led by LAPAM, a China based venture capital. The new capital will be used to expand the team and catalyze in-house CNS (central nervous system) drug discovery in both the U.S. and China. “The successful completion of this fundraising is […]

September 29, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 22 Sep 2022

Research identifies new treatment target for CNS injury and neurological disease

Researchers in Birmingham in the U.K. have identified a potential target for drugs to treat long-term neurological conditions like Alzheimer’s Disease and foster nerve regeneration in central nervous system injuries. The research, published last week in Science Advances, is part of a workstream exploring the signaling pathways that respond to DNA damage, which is seen […]

September 22, 2022 - 3 minutesmins - By Jim Cornall

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Neurological disorders

PrecisionLife to work on R&D with Ono Pharmaceutical

bit.bio expands portfolio for drug discovery in neurodegenerative and neurological diseases

Beyond Biotech podcast 23: World Antimicrobial Awareness Week, PsychoGenics

Minoryx and Neuraxpharm form alliance to get rights to new therapy for rare CNS disease

Minoryx and Neuraxpharm announce license agreement to further X-ALD treatment

PrecisionLife supports Sosei Heptares to treat chronic diseases in more personalized way

Alkermes to separate oncology business

Neuraxpharm to commercialize device giving early warning of epileptic seizures

Ascidian Therapeutics launches with $50M to rewrite RNA

Spinoff Biohaven launches with $258M and “incredible pipeline”

NeuShen Therapeutics closes $20M pre-A financing

Research identifies new treatment target for CNS injury and neurological disease

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!